Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
24
WXIBF Quote, Financials, Valuation and Earnings
Last price:
$4.04
Seasonality move
:
-29.83%
Day range:
$4.04 - $4.04
52-week range:
$1.86 - $5.61
Dividend yield:
0%
P/E ratio:
29.53x
P/S ratio:
6.10x
P/B ratio:
2.73x
Volume:
--
Avg. volume:
1.2K
1-year change:
117.67%
Market cap:
$16.4B
Revenue:
$2.6B
EPS (TTM):
$0.14
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
WXIBF
WuXi Biologics (Cayman), Inc.
|
-- | -- | -- | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -$0.34 | -- | -- | $9.22 |
|
CASI
CASI Pharmaceuticals, Inc.
|
-- | -- | -100% | -- | $4.00 |
|
CPHI
China Pharma Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$130.3M | -$0.23 | 16.92% | -46.43% | $49.49 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
WXIBF
WuXi Biologics (Cayman), Inc.
|
$4.04 | -- | $16.4B | 29.53x | $0.00 | 0% | 6.10x |
|
ADAG
Adagene, Inc.
|
$1.99 | $9.22 | $93.7M | -- | $0.00 | 0% | 895.61x |
|
CASI
CASI Pharmaceuticals, Inc.
|
$0.96 | $4.00 | $19.7M | -- | $0.00 | 0% | 0.56x |
|
CPHI
China Pharma Holdings, Inc.
|
$1.70 | -- | $5.5M | -- | $0.00 | 0% | 1.37x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
ZLAB
Zai Lab Ltd.
|
$19.50 | $49.49 | $2.2B | -- | $0.00 | 0% | 4.74x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
WXIBF
WuXi Biologics (Cayman), Inc.
|
5.93% | -1.255 | -- | 1.98x |
|
ADAG
Adagene, Inc.
|
26.49% | 2.508 | -- | 2.23x |
|
CASI
CASI Pharmaceuticals, Inc.
|
-274.41% | 0.019 | 55.28% | 0.19x |
|
CPHI
China Pharma Holdings, Inc.
|
29.58% | -1.772 | 56.09% | 0.09x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.067 | 12.91% | 11.22x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | 0.005 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
WXIBF
WuXi Biologics (Cayman), Inc.
|
-- | -- | 7.16% | 7.53% | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -- | -42.07% | -56.44% | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
$706K | -$10.2M | -405.32% | -70405.41% | -333.14% | -- |
|
CPHI
China Pharma Holdings, Inc.
|
-$257.6K | -$628.1K | -29.08% | -43.41% | -83.07% | -$277.6K |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
WuXi Biologics (Cayman), Inc. vs. Competitors
-
Which has Higher Returns WXIBF or ADAG?
Adagene, Inc. has a net margin of -- compared to WuXi Biologics (Cayman), Inc.'s net margin of --. WuXi Biologics (Cayman), Inc.'s return on equity of 7.53% beat Adagene, Inc.'s return on equity of -56.44%.
Company Gross Margin Earnings Per Share Invested Capital WXIBFWuXi Biologics (Cayman), Inc.-- -- $6.6B ADAGAdagene, Inc.-- -- $68.7M -
What do Analysts Say About WXIBF or ADAG?
WuXi Biologics (Cayman), Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Adagene, Inc. has an analysts' consensus of $9.22 which suggests that it could grow by 363.53%. Given that Adagene, Inc. has higher upside potential than WuXi Biologics (Cayman), Inc., analysts believe Adagene, Inc. is more attractive than WuXi Biologics (Cayman), Inc..
Company Buy Ratings Hold Ratings Sell Ratings WXIBFWuXi Biologics (Cayman), Inc.0 0 0 ADAGAdagene, Inc.6 2 0 -
Is WXIBF or ADAG More Risky?
WuXi Biologics (Cayman), Inc. has a beta of 0.038, which suggesting that the stock is 96.235% less volatile than S&P 500. In comparison Adagene, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock WXIBF or ADAG?
WuXi Biologics (Cayman), Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adagene, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. WuXi Biologics (Cayman), Inc. pays -- of its earnings as a dividend. Adagene, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WXIBF or ADAG?
WuXi Biologics (Cayman), Inc. quarterly revenues are --, which are smaller than Adagene, Inc. quarterly revenues of --. WuXi Biologics (Cayman), Inc.'s net income of -- is lower than Adagene, Inc.'s net income of --. Notably, WuXi Biologics (Cayman), Inc.'s price-to-earnings ratio is 29.53x while Adagene, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WuXi Biologics (Cayman), Inc. is 6.10x versus 895.61x for Adagene, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WXIBFWuXi Biologics (Cayman), Inc.6.10x 29.53x -- -- ADAGAdagene, Inc.895.61x -- -- --
-
Which has Higher Returns WXIBF or CASI?
CASI Pharmaceuticals, Inc. has a net margin of -- compared to WuXi Biologics (Cayman), Inc.'s net margin of -353.92%. WuXi Biologics (Cayman), Inc.'s return on equity of 7.53% beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.
Company Gross Margin Earnings Per Share Invested Capital WXIBFWuXi Biologics (Cayman), Inc.-- -- $6.6B CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M -
What do Analysts Say About WXIBF or CASI?
WuXi Biologics (Cayman), Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 316.62%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than WuXi Biologics (Cayman), Inc., analysts believe CASI Pharmaceuticals, Inc. is more attractive than WuXi Biologics (Cayman), Inc..
Company Buy Ratings Hold Ratings Sell Ratings WXIBFWuXi Biologics (Cayman), Inc.0 0 0 CASICASI Pharmaceuticals, Inc.0 0 0 -
Is WXIBF or CASI More Risky?
WuXi Biologics (Cayman), Inc. has a beta of 0.038, which suggesting that the stock is 96.235% less volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.853, suggesting its less volatile than the S&P 500 by 14.657%.
-
Which is a Better Dividend Stock WXIBF or CASI?
WuXi Biologics (Cayman), Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. WuXi Biologics (Cayman), Inc. pays -- of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WXIBF or CASI?
WuXi Biologics (Cayman), Inc. quarterly revenues are --, which are smaller than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. WuXi Biologics (Cayman), Inc.'s net income of -- is lower than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, WuXi Biologics (Cayman), Inc.'s price-to-earnings ratio is 29.53x while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WuXi Biologics (Cayman), Inc. is 6.10x versus 0.56x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WXIBFWuXi Biologics (Cayman), Inc.6.10x 29.53x -- -- CASICASI Pharmaceuticals, Inc.0.56x -- $3.1M -$10.9M
-
Which has Higher Returns WXIBF or CPHI?
China Pharma Holdings, Inc. has a net margin of -- compared to WuXi Biologics (Cayman), Inc.'s net margin of -86.16%. WuXi Biologics (Cayman), Inc.'s return on equity of 7.53% beat China Pharma Holdings, Inc.'s return on equity of -43.41%.
Company Gross Margin Earnings Per Share Invested Capital WXIBFWuXi Biologics (Cayman), Inc.-- -- $6.6B CPHIChina Pharma Holdings, Inc.-34.07% -$0.17 $12.1M -
What do Analysts Say About WXIBF or CPHI?
WuXi Biologics (Cayman), Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand China Pharma Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that WuXi Biologics (Cayman), Inc. has higher upside potential than China Pharma Holdings, Inc., analysts believe WuXi Biologics (Cayman), Inc. is more attractive than China Pharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings WXIBFWuXi Biologics (Cayman), Inc.0 0 0 CPHIChina Pharma Holdings, Inc.0 0 0 -
Is WXIBF or CPHI More Risky?
WuXi Biologics (Cayman), Inc. has a beta of 0.038, which suggesting that the stock is 96.235% less volatile than S&P 500. In comparison China Pharma Holdings, Inc. has a beta of 1.028, suggesting its more volatile than the S&P 500 by 2.826%.
-
Which is a Better Dividend Stock WXIBF or CPHI?
WuXi Biologics (Cayman), Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. WuXi Biologics (Cayman), Inc. pays -- of its earnings as a dividend. China Pharma Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WXIBF or CPHI?
WuXi Biologics (Cayman), Inc. quarterly revenues are --, which are smaller than China Pharma Holdings, Inc. quarterly revenues of $756.2K. WuXi Biologics (Cayman), Inc.'s net income of -- is lower than China Pharma Holdings, Inc.'s net income of -$651.5K. Notably, WuXi Biologics (Cayman), Inc.'s price-to-earnings ratio is 29.53x while China Pharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WuXi Biologics (Cayman), Inc. is 6.10x versus 1.37x for China Pharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WXIBFWuXi Biologics (Cayman), Inc.6.10x 29.53x -- -- CPHIChina Pharma Holdings, Inc.1.37x -- $756.2K -$651.5K
-
Which has Higher Returns WXIBF or SVA?
Sinovac Biotech Ltd. has a net margin of -- compared to WuXi Biologics (Cayman), Inc.'s net margin of --. WuXi Biologics (Cayman), Inc.'s return on equity of 7.53% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital WXIBFWuXi Biologics (Cayman), Inc.-- -- $6.6B SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About WXIBF or SVA?
WuXi Biologics (Cayman), Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that WuXi Biologics (Cayman), Inc. has higher upside potential than Sinovac Biotech Ltd., analysts believe WuXi Biologics (Cayman), Inc. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings WXIBFWuXi Biologics (Cayman), Inc.0 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is WXIBF or SVA More Risky?
WuXi Biologics (Cayman), Inc. has a beta of 0.038, which suggesting that the stock is 96.235% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.723, suggesting its less volatile than the S&P 500 by 27.741%.
-
Which is a Better Dividend Stock WXIBF or SVA?
WuXi Biologics (Cayman), Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. WuXi Biologics (Cayman), Inc. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios WXIBF or SVA?
WuXi Biologics (Cayman), Inc. quarterly revenues are --, which are smaller than Sinovac Biotech Ltd. quarterly revenues of --. WuXi Biologics (Cayman), Inc.'s net income of -- is lower than Sinovac Biotech Ltd.'s net income of --. Notably, WuXi Biologics (Cayman), Inc.'s price-to-earnings ratio is 29.53x while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WuXi Biologics (Cayman), Inc. is 6.10x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WXIBFWuXi Biologics (Cayman), Inc.6.10x 29.53x -- -- SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns WXIBF or ZLAB?
Zai Lab Ltd. has a net margin of -- compared to WuXi Biologics (Cayman), Inc.'s net margin of -30.98%. WuXi Biologics (Cayman), Inc.'s return on equity of 7.53% beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital WXIBFWuXi Biologics (Cayman), Inc.-- -- $6.6B ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About WXIBF or ZLAB?
WuXi Biologics (Cayman), Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab Ltd. has an analysts' consensus of $49.49 which suggests that it could grow by 153.79%. Given that Zai Lab Ltd. has higher upside potential than WuXi Biologics (Cayman), Inc., analysts believe Zai Lab Ltd. is more attractive than WuXi Biologics (Cayman), Inc..
Company Buy Ratings Hold Ratings Sell Ratings WXIBFWuXi Biologics (Cayman), Inc.0 0 0 ZLABZai Lab Ltd.8 1 0 -
Is WXIBF or ZLAB More Risky?
WuXi Biologics (Cayman), Inc. has a beta of 0.038, which suggesting that the stock is 96.235% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.872, suggesting its less volatile than the S&P 500 by 12.778%.
-
Which is a Better Dividend Stock WXIBF or ZLAB?
WuXi Biologics (Cayman), Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. WuXi Biologics (Cayman), Inc. pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WXIBF or ZLAB?
WuXi Biologics (Cayman), Inc. quarterly revenues are --, which are smaller than Zai Lab Ltd. quarterly revenues of $116.2M. WuXi Biologics (Cayman), Inc.'s net income of -- is lower than Zai Lab Ltd.'s net income of -$36M. Notably, WuXi Biologics (Cayman), Inc.'s price-to-earnings ratio is 29.53x while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WuXi Biologics (Cayman), Inc. is 6.10x versus 4.74x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WXIBFWuXi Biologics (Cayman), Inc.6.10x 29.53x -- -- ZLABZai Lab Ltd.4.74x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
50
TGL alert for Dec 8
Treasure Global, Inc. [TGL] is up 31.68% over the past day.
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 45.78% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 8.15% over the past day.
